Very low levels of HDL cholesterol and atherosclerosis, a variable relationship - A review of LCAT deficiency

Vascular Health and Risk Management

Volumn 8, Issue 1, 2012, Pages 357-361

  Savel, Julia ^a,b   Lafitte, Marianne ^a   Pucheu, Yann ^a,c   Pradeau, Vincent ^a   Tabarin, Antoine ^b,c   Couffinhal, Thierry ^a,c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c Bordeaux Segalen University   (France)

Author keywords

Atherosclerosis; Cardiovascular risk; High density lipoprotein; LCAT function

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; BIOLOGICAL MARKER;

ATHEROSCLEROSIS; BIOCHEMISTRY; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CLINICAL FEATURE; DISEASE SEVERITY; ENZYME ACTIVITY; GENE EXPRESSION; GENE LOCATION; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOSITY; HUMAN; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; LECITHIN CHOLESTEROL ACYLTRANSFERASE GENE; PREVALENCE; PROTEIN CLEAVAGE; REVIEW; RISK FACTOR; SEQUENCE ANALYSIS; ANIMAL; BLOOD; CASE REPORT; DISEASE COURSE; ENZYMOLOGY; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PROGNOSIS; RISK ASSESSMENT;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; DISEASE PROGRESSION; FEMALE; HUMANS; LECITHIN ACYLTRANSFERASE DEFICIENCY; MIDDLE AGED; MUTATION; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84867661481     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S29985     Document Type: Review

References (18)

1. Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med. 1989;321(19):1311-1316
2. Barter P, Gotto AM, LaRosa JC, et al. Hdl cholesterol, very low levels of ldl cholesterol, and cardiovascular events. N Engl J Med. 2007; 357(13):1301-1310
3. Czarnecka H, Yokoyama S. Regulation of cellular cholesterol efflux by lecithin: Cholesterol acyltransferase reaction through nonspecific lipid exchange. J Biol Chem. 1996;271(4):2023-2028
4. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin: Cholesterol acyltransferase (lcat) deficiency syndromes. J Lipid Res. 1997;38(2):191-205
5. Calabresi L, Pisciotta L, Costantin A, et al. The molecular basis of lecithin: Cholesterol acyltransferase deficiency syndromes: A comprehensive study of molecular and biochemical findings in 13 unrelated italian families. Arterioscler Thromb Vasc Biol. 2005;25(9):1972-1978
6. Hovingh GK, de Groot E, van der Steeg W, et al. Inherited disorders of hdl metabolism and atherosclerosis. Curr Opin Lipidol. 2005; 16(2):139-145
7. Klein HG, Santamarina-Fojo S, Duverger N, et al. Fish eye syndrome: A molecular defect in the lecithin-cholesterol acyltransferase (lcat) gene associated with normal alpha-lcat-specific activity. Implications for classification and prognosis. J Clin Invest. 1993;92(1):479-485
8. Calabresi L, Baldassarre D, Castelnuovo S, et al. Functional lecithin: Cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation. 2009;120(7):628-635
9. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: From bench to bedside. Arterioscler Thromb Vasc Biol. 2003;23(10):1724-1731
10. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: Key to the regression of atherosclerosis? Circulation. 2006;113(21):2548-2555
11. Wells IC, Peitzmeier G, Vincent JK. Lecithin: Cholesterol acyltransferase and lysolecithin in coronary atherosclerosis. Exp Mol Pathol. 1986;45(3):303-310
12. Solajic-Bozicevic N, Stavljenic-Rukavina A, Sesto M. Lecithincholesterol acryltransferase activity in patients with coronary artery disease examined by coronary angiography. Clin Investig. 1994;72(12): 951-956
13. Hovingh GK, Hutten BA, Holleboom AG, et al. Compromised lcat function is associated with increased atherosclerosis. Circulation. 2005;112(6):879-884
14. Ayyobi AF, McGladdery SH, Chan S, John Mancini GB, Hill JS, Frohlich JJ. Lecithin: Cholesterol acyltransferase (lcat) deficiency and risk of vascular disease: 25 year follow-up. Atherosclerosis. 2004;177(2):361-366
15. Lafitte M, Pradeau V, Leroux L, et al. Efficacy over time of a short overall atherosclerosis management programme on the reduction of cardiovascular risk in patients after an acute coronary syndrome. Arch Cardiovasc Dis. 2009;102(1):51-58
16. Riedel M, Lafitte M, Pucheu Y, Latry K, Couffinhal T. Prognostic value of high-sensitivity c-reactive protein in a population of post-acute coronary syndrome patients receiving optimal medical treatment. Eur J Cardiovasc Prev Rehabil. 2011 Sep 7. [Epub ahead of print]
17. Rader DJ, Ikewaki K, Duverger N, et al. Markedly accelerated catabolism of apolipoprotein a-ii (apoa-ii) and high density lipoproteins containing apoa-ii in classic lecithin: Cholesterol acyltransferase deficiency and fish-eye disease. J Clin Invest. 1994;93(1):321-330
18. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127-135.